SRRA Key Statistics, Chart & Performance
The current stock price of SRRA is 54.99 null. In the past month the price increased by 0.38%. In the past year, price increased by 178.43%.
SRRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.86B |
Related stock screener links
About SRRA
Company Profile
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The company is headquartered in Vancouver, British Columbia and currently employs 109 full-time employees. The company went IPO on 2015-07-16. The Company’s lead product candidate, momelotinib, which is a selective and orally bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor under investigation for the treatment of myelofibrosis. The firm is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), which is a key regulator of cell cycle progression and the DDR network. SRA141 is a bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
Company Info
Sierra Oncology Inc
2150 ? 885 West Georgia Street, Suite 110
Vancouver BRITISH COLUMBIA V6C 3E8 CA
CEO: Stephen G. Dilly
Employees: 109
Phone: 16045586536.0
Sierra Oncology Inc / SRRA FAQ
Can you describe the business of Sierra Oncology Inc?
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The company is headquartered in Vancouver, British Columbia and currently employs 109 full-time employees. The company went IPO on 2015-07-16. The Company’s lead product candidate, momelotinib, which is a selective and orally bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor under investigation for the treatment of myelofibrosis. The firm is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), which is a key regulator of cell cycle progression and the DDR network. SRA141 is a bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
What is the current price of SRRA stock?
The current stock price of SRRA is 54.99 null. The price increased by 0.04% in the last trading session.
Does Sierra Oncology Inc pay dividends?
SRRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of SRRA stock?
SRRA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of Sierra Oncology Inc (SRRA) based on its PE ratio?
Sierra Oncology Inc (SRRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.77).
SRRA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SRRA. When comparing the yearly performance of all stocks, SRRA is one of the better performing stocks in the market, outperforming 99.87% of all stocks.
SRRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SRRA. While SRRA has a great health rating, there are worries on its profitability.
SRRA Financial Highlights
Over the last trailing twelve months SRRA reported a non-GAAP Earnings per Share(EPS) of -6.77. The EPS decreased by -7.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.67% | ||
| ROE | N/A | ||
| Debt/Equity | 0.02 |
SRRA Forecast & Estimates
10 analysts have analysed SRRA and the average price target is 56.1 null. This implies a price increase of 2.02% is expected in the next year compared to the current price of 54.99.